excluding non-melanoma skin cancer) were observed at a rate of 0.5 per 100 patient-years among 4,650 Cimzia®
-treated patients versus a rate of 0.6 per 100 patient-years among 1,319 placebo-treated patients. In studies of Cimzia®
for Crohn's disease and other investigational uses, there was one case of lymphoma among 2,657 Cimzia®
-treated patients and one case of Hodgkin lymphoma among 1,319 placebo-treated patients. In Cimzia®
RA clinical trials (placebo-controlled and open label) a total of three cases of lymphoma were observed among 2,367 patients. This is approximately 2-fold higher than expected in the general population. Patients with RA, particularly those with highly active disease, are at a higher risk for the development of lymphoma. The potential role of TNF blocker therapy in the development of malignancies is not known.
Cases of worsening congestive heart failure (CHF) and new onset CHF have been reported with TNF blockers. Cimzia® has not been formally studied in patients with CHF. Exercise caution when using Cimzia® in patients who have heart failure and monitor them carefully.
Symptoms compatible with hypersensitivity reactions, including angioedema, dyspnea, hypotension, rash, serum sickness, and urticaria, have been reported rarely following Cimzia® administration. If such reactions occur, discontinue further administration of Cimzia® and institute appropriate therapy.
Hepatitis B Reactivation
Use of TNF blockers, including Cimzia®, may increase the risk of reactivation of hepatitis B virus (HBV) in patients who are chronic carriers of this virus. Some cases have been fatal. Evaluate patients at risk for HBV infection for prior evidence of HBV infection before initiating Cimzia® therapy. Exercise caution in prePage: 1 2 3 4 5 6 7 8 9 10 11 12 Related biology technology :1
. Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohns Patients2
. New Data Suggest CIMZIA(R) (Certolizumab Pegol) Active in Treating Moderate to Severe Crohns Patients With Fistulizing Disease3
. FDA Agrees to Review Cimzia(R) File for the Treatment of Rheumatoid Arthritis4
. Tiny test tube experiment shows reaction of melting materials at the nano scale5
. New Survey Shows Devastating Impact of Rheumatoid Arthritis Pain on Intimate Relations6
. Topical erectile dysfunction therapy shows promise7
. Study on keeping nuclear bombs from US ports shows misplaced fear over cargo scanning cost8
. Medicagos H1N1 pandemic vaccine candidate shows positive response in 100% of vaccinated animals after a single dose9
. Video shows nanotube spins as it grows10
. MuGard Data From UK Study Shows Prevention of Oral Mucositis in Head and Neck Cancer Patients11
. Investigational Urine NGAL Biomarker Shows Promise to Monitor Cyclosporine Toxicity in Cardiac Transplant Patients